Key takeaways
Emgality (galcanezumab) and Zomig (zolmitriptan) are both used to manage migraines, but they work differently and are used in different ways. Emgality is a monoclonal antibody that prevents migraines and treats cluster headaches by blocking a protein called calcitonin-gene related peptide (CGRP). It is given as a monthly injection under the skin. On the other hand, Zomig is a triptan that treats migraines by attaching to serotonin receptors to reduce blood vessel swelling and pain signals. Zomig is taken as needed at the first sign of a migraine and comes in tablet, orally disintegrating tablet, and nasal spray forms. Emgality is only available as a brand-name medication, while Zomig is available in both brand-name and generic forms. Emgality is used for prevention, whereas Zomig is used for immediate relief. Common side effects of Emgality include injection site reactions, while Zomig can cause dizziness and chest pain.
